- Recommendation ID
- TA245/1
- Question
- More trials of apixaban compared with other low molecular weight heparin (LMWHs) in total hip and knee replacement would decrease the uncertainty of the clinical and cost effectiveness of these treatments. Trials directly comparing apixaban with rivaroxaban, dabigatran etexilate and fondaparinux would strengthen the evidence base for these comparisons.
- Any explanatory notes
(if applicable) - None.
Source guidance details
- Comes from guidance
- Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
- Number
- TA245
- Date issued
- January 2012
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |